Further Outpatient Care
See the list below:
-
Postoperative
-
Radiation therapy
-
Chemotherapy
Further Inpatient Care
See the list below:
-
Postoperative
-
Chemotherapy
Complications
See the list below:
-
Postoperative complications
Cranial nerve palsy
Meningitis
Paralysis
Cognitive dysfunction
-
Carcinomatous meningitis
-
Wound infection
-
Immunosuppression due to chemotherapy and radiation therapy
-
Recurrence
-
Metastasis
Prognosis
See the list below:
-
Osteosarcoma has a 5-year survival rate between 20% and 50%.
-
Chondrosarcoma has a 10-year survival rate of 30-80%, depending on the grade of the initial tumor.
-
Fibrosarcomas metastasize in 50% of cases, and the 10-year survival rate is 40%.
-
Ewing sarcoma has a 5-year survival rate of 40-65%.
-
Giant cell tumor has a recurrence rate of 30% in 2 years, but otherwise its prognosis is relatively good.
-
Angiosarcomas, if properly treated, have a cure rate of about 50%.
-
Chordomas, although difficult to resect completely, are slow-growing tumors and have a 5-year survival rate of 40%.
-
Myeloma survival rates vary depending on the grade. However, even in patients with widespread disease, complete remission can be achieved for up to 2-3 years (or longer).
Patient Education
See the list below:
-
The lesion should be identified and treated promptly.
-
If required, patients should be referred for psychological counseling.
-
Head CT scan of a 60-year-old man with a history of multiple myeloma for 2 years, showing multiple lytic lesions that involve both the inner and outer tables as well as the diploë.
-
This head CT scan shows multiple lytic lesions of the skull involving both the inner and outer tables.